China-based Dizal Pharmaceutical has presented new data at the 2026 European Lung Cancer Congress (ELCC) showing that its EGFR inhibitor, Zegfrovy (sunvozertinib), achieved an 81.3% objective response rate (ORR) in treatment-naive patients with advanced non-small cell lung cancer (NSCLC) harbouring EGFR P-loop and αC-helix compression (PACC) or other rare mutations. The disease control rate (DCR) was 100%, with tumour shrinkage observed in all patients. The therapy also showed promising activity in patients with baseline brain metastases. The safety profile was consistent with prior studies and deemed manageable.

EGFR PACC mutations, which account for approximately 12.5% of EGFR-mutant NSCLC, are associated with poor prognosis and limited treatment options. Sunvozertinib is already approved in China and the US for later-line treatment of NSCLC with EGFR exon 20 insertion mutations. The AstraZeneca spin-off recently reported positive topline results from the Phase III WU-KONG28 trial evaluating the drug in the first-line setting for that population. The new data in PACC mutations support the broad potential of sunvozertinib to address various difficult-to-treat EGFR alterations.

According to PharmCube's NextBiopharm® database, sunvozertinib is the only approved EGFR exon 20 inhibitor worldwide. Click here to request a free trial for NextBiopharm®.